A literature review was conducted to assess risk of cardiac valve regurgitation (CVR) associated with use of ergot-derived and non-ergot dopamine agonists (DAs) in patients with Parkinson's disease (PD). Inclusion criteria: case-control/observational studies of >10 patients with PD treated with DAs, including a control group and assessment of incidence/risk of CVR. Of the 166 publications identified, 14 met all inclusion criteria and included 1,750 patients. In 11 of the studies, a significant increase in CVR frequency of any severity (at the aortic, mitral or tricuspid valve) in the ergot group vs. the non-ergot or control group was described. No study reported increased risk of CVR for non-ergot DAs, compared with controls. In the studies identified in the literature, the use of ergot-derived DAs (pergolide and cabergoline) in patients with PD was associated with increased risk of CVR. Increased risk of CVR was not associated with the use of non-ergot DAs. © 2009 Springer-Verlag.
CITATION STYLE
Steiger, M., Jost, W., Grandas, F., & Van Camp, G. (2009). Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: A systematic review. Journal of Neural Transmission, 116(2), 179–191. https://doi.org/10.1007/s00702-008-0179-4
Mendeley helps you to discover research relevant for your work.